Protez Pharmaceuticals of Malvern, Pennsylvania, has raised $15 million in its second round of venture capital. Protez intends to use the proceeds from the financing to accelerate development of its lead compound SMP-601, an injectable antibiotic. Release [1]
Links:
[1] http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-24-2005/0004093332&EDATE=